This is a summary of the European public assessment report (EPAR) for Spectrila. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Spectrila. For practical information about using Spectrila, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Spectrila is indicated as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years and adults.
Therapeutic Area (MeSH)
ATC Code
L01XX02
ATC Item
asparaginase
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| asparaginase | N/A | 门冬酰胺酶 |
EMA Name
Spectrila
Medicine Name
Spectrila
Aliases
N/A
